KRAS and neoplasm: In addition, no associations were found between EPHB6 expression levels and other clinicopathological features of these patients including patient sex, age, or tumor site (colon/rectum), the administration of adjuvant treatment, as well as some molecular characteristics of the tumors, including microsatellite instability, allelic loss of chromosome 18q and the presence of mutations in TP53 or KRAS (Supplementary Table 1).